An observational study in Shwachman-Diamond Syndrome, SDS and IBMF, sponsored by Shwachman-Diamond Syndrome Alliance Inc. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2025-05-31.
Sponsored by Shwachman-Diamond Syndrome Alliance Inc · Observational
The Shwachman-Diamond Syndrome Global Patient Survey and Collaboration Program (SDS-GPS) is an opportunity for patients and their families - from anywhere in the world - to share their experience living with SDS via a safe, secure, and convenient online platform, to
By joining, participants will receive early access to relevant information about new clinical trials and other research opportunities (such as clinical registries) based on their profile, accelerating research and increasing clinical trial impact and recruitment success.
The platform, consent forms, and surveys are available in five languages: English, Spanish, French, German, and Italian. More languages to come.
What is SDS-GPS?
The Shwachman-Diamond Syndrome Global Patient Survey and Collaboration Program (SDS-GPS) is an opportunity for patients and their families - from anywhere in the world - to share their experience living with SDS via a safe, secure, and convenient online platform, with the goal of
SDS-GPS was created for the patients, by the patients, with thoughtful input from patients, families, advocates, caregivers, researchers, clinicians, and regulators.
Participants will be part of a global community that cares, turns hope into action, and drives research. Participants' experience - whether it falls in the mild or severe end of the spectrum - matters. Their voice counts.
How can patients' stories help drive therapies and cures?
Participants' stories help paint a more complete picture of what SDS is and how it impacts the people living with it. Their participation helps build a strong, engaged community, which is critical to drive progress. Without patients and their families, research cannot advance.
The investigators (the SDS-GPS team at the SDS Alliance) use participants' de-identified aggregate survey responses and other data they share to develop a deeper understanding of the unmet needs of the community.
The investigators use the insights to
What aspects of their story can participants share through SDS-GPS?
Surveys on the SDS-GPS Program Platform are designed to be quick and easy, without the need to have to look up any details from medical records. They can save their progress and come back anytime.
Survey topics include:
How does SDS-GPS work?
The platform, consent forms, and surveys are available in five languages: English, Spanish, French, German, and Italian. More languages to come.
21 studies on the registry are indexed under Shwachman-Diamond Syndrome; 4 are open to participants now.
Browse Shwachman-Diamond Syndrome studies →This is the only study on the registry with Shwachman-Diamond Syndrome Alliance Inc as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Patients and their caregivers may enroll from anywhere in the world using our online platform. Individuals for whom English is not their primary language may be enrolled with a translated informed consent form (and translated surveys if available). Currently available languages include English, Spanish, French, Italian, and German.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The Program invites patients of all ages who have a confirmed diagnosis of the below, using established diagnostic guidelines, plus their parents/caregivers.
Exclusion Criteria:
● People who do not meet the above criteria.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patient (or caregiver) reported symptoms over time
Patients report symptoms via surveys, grouped by organ system.
Time frame: At baseline and every 12 months, prospectively.
Genetics report uploaded by patient (or caregiver)
Clinical genetics reports are uploaded by the patient (or caregiver) and curated by study staff to confirm a genetic diagnosis, understand variants, and assess the use of appropriate genetic testing methodologies.
Time frame: Through study completion when the genetics report is available.
Quality of life measures via PROMIS surveys
PROMIS surveys in various domains, such as fatigue, pain, anxiety, and depression, are administered as surveys and scored with the standard PROMIS scoring methods. Specific PROMIS measures to include: v1.0 Anxiety 8a short form v1.0 Depression 8a short form v1.0 Pain Interference 6a short form v2.0 Cognitive Function 8a short form v1.0 Self-Efficacy for Managing Chronic Conditions: Manage Daily Activities 8a short form v1.0 - Self-Efficacy for Managing Symptoms 8a v2.0 Satisfaction Social Roles and Activities 8a short form v2.0 Ability to Part Social Roles and Activities 8a short form v2.0 Social Isolation 8a short form v1.0 Fatigue 13a short form (FACIT-Fatigue) v3.0 PP: Depressive Symptoms 6a short form v3.0 PP: Fatigue 10a short form v3.0 PP: Mobility 7a short form v3.0 PP: Pain Interference 8a short form v1.0 PP: Cognitive Function 7a short form
Time frame: Through study completion, an average of 2-4 times per year.
Patient reported burden of disease and treatment outcomes
Patients fill out surveys to report on disease burden (such as number and duration of hospitalizations), treatment burden (such as surveillance), and treatment outcomes (such as HSC transplant outcomes)
Time frame: At baseline and every 12 months, prospectively.
Plan to share: Undecided — This study is focused on patient reported data and findings will be published in the aggregate to safeguard patient personal health information.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.